Reply. Exploring the impact of fertility-preserving treatment on pregnancy: key issues in patients with endometrial cancer and atypical hyperplasia
Human Reproduction · 2024
DOI: 10.1093/humrep/deae188 ↗Kurz gefasst
Leserbrief in der Zeitschrift Human Reproduction, 2024. Verfasst von Radostina Vasileva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, CHU Bichat-Claude Bernard, Paris, France. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Fertility Preservation, Endometrial Hyperplasia. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Sir, We thank Dr Tang and Dr Liu for their comments on our study titled ‘Pregnancy and Obstetric Outcomes After Fertility-Sparing Management of Endometrial Cancer and Atypical Hyperplasia’ (Tang and Liu, 2024; Vasileva et al., 2024). We appreciate the opportunity to address these concerns using evidence and details from our research. First, we acknowledge the concern regarding the impact of twin pregnancies. However, our medical records were carefully analyzed for the presence of multiple pregnancies, and none were found within the cohort. Among the 95 pregnancies identified, 59 resulted in singleton live births following conservative treatment for endometrial cancer (EC) and atypical hyperplasia (AH) (Vasileva et al., 2024). Consequently, the risk of cesarean delivery due to potential issues with fetal positioning, the risk of gestational diabetes mellitus, postpartum hemorrhage, and other complications could not be biased by twin pregnancies in our study. The absence of twin pregnancies in our cohort is probably attributed to adherence to the ESHRE recommendations, which suggest that ART techniques should aim for singleton pregnancies (Alteri et al., 2024). We believe that the homogeneity of this cohort of 59 singleton live pregnancies and the absence of twin pregnancies prevent potential bias and allow for better interpretation of the results regarding obstetric outcomes. Second, Polycystic Ovary Syndrome was noted as a baseline variable, which did not differ statistically between the spontaneous and ART-obtained pregnancies. We adjusted for covariates that significantly varied between the groups of spontaneous and ART-obtained pregnancies. Therefore, we did not adjust for this variable in our multivariate analysis comparing the two groups. Concerning the use of metformin—our treatment protocol was personalized and based on hysteroscopic resection of the lesion followed by progestin therapy alone until recent data showing the efficacy of metformin in association with progestin (Yang et al., 2020). Thus, metformin could not be a major source of bias. Moreover, we would like to underline that the meta-analysis by Shao et al. (2023) found that the addition of metformin in patients with endometrial hyperplasia and early EC may improve the clinical pregnancy rate (pooled OR 1.55, 95% CI 0.99–2.42, P = 0.05), but not increase the live birth rate (pooled OR 0.95, 95% CI 0.45–2.01, P = 0.89). Patients should be counseled about the realistic chances of pregnancy and, more importantly, a live birth. Lastly, detailed cancer staging was an integral part of our study, and all patients included had confirmed diagnoses of Stage 1A EC or AH. The patients’ histological slides of the endometrial tumor were systematically reviewed by a reference pathologist. A multidisciplinary committee examined each request for fertility preservation, and approval was based on European recommendations, which suggest that fertility-sparing treatment should be offered to women with anticipated Stage 1A, Grade 1 EC (Rodolakis et al., 2015). Thus, the national fertility database consists of a majority of patients presenting with low-grade EC (Querleu et al., 2017). In our cohort study, one patient had Grade 3 EC (p53 wild type) and obtained pregnancy, but statistical analysis based on this characteristic was not performed as it was not the objective of our study. As mentioned in our study, its retrospective design is a limitation to some of the interpretations. However, we present the largest cohort of patients providing evidence that conservative management of EC and AH can lead to successful pregnancy outcomes with careful monitoring and appropriate interventions. The absence of significant differences between spontaneous and ART pregnancies further supports the validity of our conclusions. We hope this clarifies the points you raised and reinforces the comprehensiveness and accuracy of our study. The authors report no conflicts of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, CHU Bichat-Claude Bernard, Paris, France.
ORCID-Profile: Radostina Vasileva, Martin Koskas
Zitieren
APA
Vasileva, R., & Koskas, M. (2024). Reply. Exploring the impact of fertility-preserving treatment on pregnancy: key issues in patients with endometrial cancer and atypical hyperplasia. Human Reproduction. https://doi.org/10.1093/humrep/deae188
Vancouver
Vasileva R, Koskas M. Reply. Exploring the impact of fertility-preserving treatment on pregnancy: key issues in patients with endometrial cancer and atypical hyperplasia. Human Reproduction. 2024. doi:10.1093/humrep/deae188
BibTeX
@article{Vasileva2024,
author = {Vasileva, Radostina and Koskas, Martin},
title = {Reply. Exploring the impact of fertility-preserving treatment on pregnancy: key issues in patients with endometrial cancer and atypical hyperplasia},
journal = {Human Reproduction},
year = {2024},
doi = {10.1093/humrep/deae188}
}
EUVIMED